A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome
- Focus Registrational; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 02 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Dec 2017.
- 04 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 30 Nov 2017.